这篇文章不错，转发给_老虎社区_美港股上老虎

土沙心
2021-10-01

这篇文章不错，转发给大家看

The Gross Law Firm Announces Class Actions on Behalf of Shareholders of ANVS, SAVA and SPPI

NEW YORK, NY / ACCESSWIRE / September 24, 2021 / The securities litigation law firm of The Gross Law

The Gross Law Firm Announces Class Actions on Behalf of Shareholders of ANVS, SAVA and SPPI

免责声明：上述内容仅代表发帖人个人观点，不构成本平台的任何投资建议。

推荐
最新

暂无评论

热议股票

关于我们·老虎社区守则·老虎社区账号管理规范·老虎社区服务协议·老虎社区隐私政策

公司名称：北京至简风宜信息技术有限公司

违法和不良信息投诉：010-5681-3562（工作时间9:30-18:30）

邮箱：service@laohu8.com

营业执照：91110105MA01A4U55R

ICP备：京ICP备18016422号

网安备：京公网安备11010502036490

关注我们

{"i18n":{"language":"zh_CN"},"data":{"magic":2,"id":864959758,"tweetId":"864959758","gmtCreate":1633050803845,"gmtModify":1633050803845,"author":{"id":3529619483987224,"idStr":"3529619483987224","authorId":3529619483987224,"authorIdStr":"3529619483987224","name":"土沙心","avatar":"https://static.tigerbbs.com/31cfea9d1619b34b8064992b60578bb8","vip":1,"userType":1,"introduction":"","boolIsFan":false,"boolIsHead":false,"crmLevel":2,"crmLevelSwitch":0,"individualDisplayBadges":[],"fanSize":0,"starInvestorFlag":false},"themes":[],"images":[],"coverImages":[],"extraTitle":"","html":"<html><head></head><body>\n这篇文章不错，转发给大家看</body></html>","htmlText":"<html><head></head><body>\n这篇文章不错，转发给大家看</body></html>","text":"这篇文章不错，转发给大家看","highlighted":1,"essential":1,"paper":1,"likeSize":0,"commentSize":0,"repostSize":0,"favoriteSize":0,"link":"https://laohu8.com/post/864959758","repostId":2169906556,"repostType":2,"repost":{"id":"2169906556","pubTimestamp":1632476400,"share":"https://www.laohu8.com/m/news/2169906556?lang=&edition=full","pubTime":"2021-09-24 17:40","market":"us","language":"en","title":"The Gross Law Firm Announces Class Actions on Behalf of Shareholders of ANVS, SAVA and SPPI","url":"https://stock-news.laohu8.com/highlight/detail?id=2169906556","media":"ACCESSWIRE","summary":"NEW YORK, NY / ACCESSWIRE / September 24, 2021 / The securities litigation law firm of The Gross Law","content":"<html><body><p><strong>NEW YORK, NY / ACCESSWIRE / September 24, 2021 /</strong> The securities litigation law firm of The Gross Law Firm issues the following notice on behalf of shareholders in the following publicly traded companies. Shareholders who purchased shares in the following companies during the dates listed are encouraged to contact the firm regarding possible Lead Plaintiff appointment. Appointment as Lead Plaintiff is not required to partake in any recovery.</p>\n<p><strong><a href=\"https://laohu8.com/S/ANVS\">Annovis Bio, Inc.</a> (NYSE:ANVS)</strong></p>\n<p><strong>Investors Affected : May 21, 2021 - July 28, 2021</strong></p>\n<p>A class action has commenced on behalf of certain shareholders in Annovis Bio, Inc. The filed complaint alleges that defendants made materially false and/or misleading statements and/or failed to disclose that: (1) Annovis's ANVS401 (Posiphen), an orally administrated drug which purportedly inhibited the synthesis of neurotoxic proteins that are the main cause of neurodegeneration, did not show statistically significant results across two patient populations as to factors such as orientation, judgement, and problem solving; and (2) as a result of the foregoing, Defendants' positive statements about the Company's business, operations, and prospects were materially misleading and/or lacked a reasonable basis.</p>\n<p>Shareholders may find more information at https://securitiesclasslaw.com/securities/annovis-bio-inc-loss-submission-form/?id=19831&amp;from=1</p>\n<p><strong>Cassava Sciences, Inc. (NASDAQ:SAVA)</strong></p>\n<p><strong>Investors Affected : February 2, 2021 - August 24, 2021</strong></p>\n<p>A class action has commenced on behalf of certain shareholders in Cassava Sciences, Inc. The filed complaint alleges that defendants made materially false and/or misleading statements and/or failed to disclose that: (a) the quality and integrity of the scientific data supporting Cassava's claims for simufilam's, a small molecule drug designed to treat Alzheimer's disease, efficacy had been overstated; (b) the scientific data supporting Cassava's claims for simufilam's efficacy were biased; and (c) as a result of the foregoing, Defendants' positive statements during the Class Period about the Company's business metrics and financial prospects and the likelihood of Food and Drug Administration approval were false and misleading and/or lacked a reasonable basis.</p>\n<p>Shareholders may find more information at https://securitiesclasslaw.com/securities/cassava-sciences-inc-loss-submission-form/?id=19831&amp;from=1</p>\n<p><strong><a href=\"https://laohu8.com/S/SPPI\">Spectrum Pharmaceuticals</a>, Inc. (NASDAQ:SPPI)</strong></p>\n<p><strong>Investors Affected : December 27, 2018 - August 5, 2021</strong></p>\n<p>A class action has commenced on behalf of certain shareholders in Spectrum Pharmaceuticals, Inc. The filed complaint alleges that defendants made materially false and/or misleading statements and/or failed to disclose that: (i) the manufacturing facility for ROLONTIS, an investigational granulocyte-colony stimulating factor analog, maintained deficient controls and/or procedures; (ii) the foregoing deficiencies decreased the likelihood that the Food and Drug Administration would approve the ROLONTIS biologics license application (\"BLA\") in its current form; (iii) Spectrum had therefore materially overstated the ROLONTIS BLA's approval prospects; and (iv) as a result, the Company's public statements were materially false and misleading at all relevant times.</p>\n<p>Shareholders may find more information at https://securitiesclasslaw.com/securities/spectrum-pharmaceuticals-inc-loss-submission-form/?id=19831&amp;from=1</p>\n<img src=\"https://s1.yimg.com/uu/api/res/1.2/_dArTqg0kdSMaTh9HfLx7w--/cT03NTthcHBpZD15dmlkZW9mZWVkczs-/https://media.zenfs.com/en/accesswire.ca/336d370de0572a2b77b4445d8eff3c6c\"/>\n<p>The Gross Law Firm is committed to ensuring that companies adhere to responsible business practices and engage in good corporate citizenship. The firm seeks recovery on behalf of investors who incurred losses when false and/or misleading statements or the omission of material information by a Company lead to artificial inflation of the Company's stock. Attorney advertising. Prior results do not guarantee similar outcomes.</p>\n<p><strong>CONTACT:</strong><br/>The Gross Law Firm<br/>15 West 38th Street, 12th floor<br/>New York, NY, 10018<br/>Email: dg@securitiesclasslaw.com<br/>Phone: (212) 537-9430<br/>Fax: (833) 862-7770</p>\n<p><strong>SOURCE: </strong>The Gross Law Firm</p>\n<br/>\n<br/>View source version on accesswire.com: \n<br/>\nhttps://www.accesswire.com/665413/The-Gross-Law-Firm-Announces-Class-Actions-on-Behalf-of-Shareholders-of-ANVS-SAVA-and-SPPI\n<br/>\n<br/>\n<img height=\"0\" src=\"https://www.accesswire.com/img.ashx?id=665413\" width=\"0\"/></body></html>","source":"yahoofinance","collect":0,"html":"<!DOCTYPE html>\n<html>\n<head>\n<meta http-equiv=\"Content-Type\" content=\"text/html; charset=utf-8\" />\n<meta name=\"viewport\" content=\"width=device-width,initial-scale=1.0,minimum-scale=1.0,maximum-scale=1.0,user-scalable=no\"/>\n<meta name=\"format-detection\" content=\"telephone=no,email=no,address=no\" />\n<title>The Gross Law Firm Announces Class Actions on Behalf of Shareholders of ANVS, SAVA and SPPI</title>\n<style type=\"text/css\">\na,abbr,acronym,address,applet,article,aside,audio,b,big,blockquote,body,canvas,caption,center,cite,code,dd,del,details,dfn,div,dl,dt,\nem,embed,fieldset,figcaption,figure,footer,form,h1,h2,h3,h4,h5,h6,header,hgroup,html,i,iframe,img,ins,kbd,label,legend,li,mark,menu,nav,\nobject,ol,output,p,pre,q,ruby,s,samp,section,small,span,strike,strong,sub,summary,sup,table,tbody,td,tfoot,th,thead,time,tr,tt,u,ul,var,video{ font:inherit;margin:0;padding:0;vertical-align:baseline;border:0 }\nbody{ font-size:16px; line-height:1.5; color:#999; background:transparent; }\n.wrapper{ overflow:hidden;word-break:break-all;padding:10px; }\nh1,h2{ font-weight:normal; line-height:1.35; margin-bottom:.6em; }\nh3,h4,h5,h6{ line-height:1.35; margin-bottom:1em; }\nh1{ font-size:24px; }\nh2{ font-size:20px; }\nh3{ font-size:18px; }\nh4{ font-size:16px; }\nh5{ font-size:14px; }\nh6{ font-size:12px; }\np,ul,ol,blockquote,dl,table{ margin:1.2em 0; }\nul,ol{ margin-left:2em; }\nul{ list-style:disc; }\nol{ list-style:decimal; }\nli,li p{ margin:10px 0;}\nimg{ max-width:100%;display:block;margin:0 auto 1em; }\nblockquote{ color:#B5B2B1; border-left:3px solid #aaa; padding:1em; }\nstrong,b{font-weight:bold;}\nem,i{font-style:italic;}\ntable{ width:100%;border-collapse:collapse;border-spacing:1px;margin:1em 0;font-size:.9em; }\nth,td{ padding:5px;text-align:left;border:1px solid #aaa; }\nth{ font-weight:bold;background:#5d5d5d; }\n.symbol-link{font-weight:bold;}\n/* header{ border-bottom:1px solid #494756; } */\n.title{ margin:0 0 8px;line-height:1.3;color:#ddd; }\n.meta {color:#5e5c6d;font-size:13px;margin:0 0 .5em; }\na{text-decoration:none; color:#2a4b87;}\n.meta .head { display: inline-block; overflow: hidden}\n.head .h-thumb { width: 30px; height: 30px; margin: 0; padding: 0; border-radius: 50%; float: left;}\n.head .h-content { margin: 0; padding: 0 0 0 9px; float: left;}\n.head .h-name {font-size: 13px; color: #eee; margin: 0;}\n.head .h-time {font-size: 11px; color: #7E829C; margin: 0;line-height: 11px;}\n.small {font-size: 12.5px; display: inline-block; transform: scale(0.9); -webkit-transform: scale(0.9); transform-origin: left; -webkit-transform-origin: left;}\n.smaller {font-size: 12.5px; display: inline-block; transform: scale(0.8); -webkit-transform: scale(0.8); transform-origin: left; -webkit-transform-origin: left;}\n.bt-text {font-size: 12px;margin: 1.5em 0 0 0}\n.bt-text p {margin: 0}\n</style>\n</head>\n<body>\n<div class=\"wrapper\">\n<header>\n<h2 class=\"title\">\nThe Gross Law Firm Announces Class Actions on Behalf of Shareholders of ANVS, SAVA and SPPI\n</h2>\n\n<h4 class=\"meta\">\n\n\n2021-09-24 17:40 GMT+8&nbsp;&nbsp;&nbsp;<a href=https://finance.yahoo.com/news/gross-law-firm-announces-class-094000567.html><strong>ACCESSWIRE</strong></a>\n\n\n</h4>\n\n</header>\n<article>\n<div>\n<p>NEW YORK, NY / ACCESSWIRE / September 24, 2021 / The securities litigation law firm of The Gross Law Firm issues the following notice on behalf of shareholders in the following publicly traded ...</p>\n\n<a href=\"https://finance.yahoo.com/news/gross-law-firm-announces-class-094000567.html\">Web Link</a>\n\n</div>\n\n\n</article>\n</div>\n</body>\n</html>\n","type":0,"thumbnail":"https://s.yimg.com/uu/api/res/1.2/gmtygS1bM76myqBEUYIlrQ--~B/aD05MTc7dz05MTg7YXBwaWQ9eXRhY2h5b24-/https://s.yimg.com/uu/api/res/1.2/Q8V8eFrlgC_8aPTxyhh1cw--~B/aD05MTc7dz05MTg7YXBwaWQ9eXRhY2h5b24-/https://media.zenfs.com/en/accesswire.ca/336d370de0572a2b77b4445d8eff3c6c","relate_stocks":{"SPPI":"Spectrum Pharmaceuticals","CRCT":"Cricut, Inc.","SAVA":"Cassava Sciences Inc","TERN":"Terns Pharmaceuticals, Inc.","ANVS":"Annovis Bio, Inc."},"source_url":"https://finance.yahoo.com/news/gross-law-firm-announces-class-094000567.html","is_english":true,"share_image_url":"https://static.laohu8.com/5f26f4a48f9cb3e29be4d71d3ba8c038","article_id":"2169906556","content_text":"NEW YORK, NY / ACCESSWIRE / September 24, 2021 / The securities litigation law firm of The Gross Law Firm issues the following notice on behalf of shareholders in the following publicly traded companies. Shareholders who purchased shares in the following companies during the dates listed are encouraged to contact the firm regarding possible Lead Plaintiff appointment. Appointment as Lead Plaintiff is not required to partake in any recovery.\nAnnovis Bio, Inc. (NYSE:ANVS)\nInvestors Affected : May 21, 2021 - July 28, 2021\nA class action has commenced on behalf of certain shareholders in Annovis Bio, Inc. The filed complaint alleges that defendants made materially false and/or misleading statements and/or failed to disclose that: (1) Annovis's ANVS401 (Posiphen), an orally administrated drug which purportedly inhibited the synthesis of neurotoxic proteins that are the main cause of neurodegeneration, did not show statistically significant results across two patient populations as to factors such as orientation, judgement, and problem solving; and (2) as a result of the foregoing, Defendants' positive statements about the Company's business, operations, and prospects were materially misleading and/or lacked a reasonable basis.\nShareholders may find more information at https://securitiesclasslaw.com/securities/annovis-bio-inc-loss-submission-form/?id=19831&from=1\nCassava Sciences, Inc. (NASDAQ:SAVA)\nInvestors Affected : February 2, 2021 - August 24, 2021\nA class action has commenced on behalf of certain shareholders in Cassava Sciences, Inc. The filed complaint alleges that defendants made materially false and/or misleading statements and/or failed to disclose that: (a) the quality and integrity of the scientific data supporting Cassava's claims for simufilam's, a small molecule drug designed to treat Alzheimer's disease, efficacy had been overstated; (b) the scientific data supporting Cassava's claims for simufilam's efficacy were biased; and (c) as a result of the foregoing, Defendants' positive statements during the Class Period about the Company's business metrics and financial prospects and the likelihood of Food and Drug Administration approval were false and misleading and/or lacked a reasonable basis.\nShareholders may find more information at https://securitiesclasslaw.com/securities/cassava-sciences-inc-loss-submission-form/?id=19831&from=1\nSpectrum Pharmaceuticals, Inc. (NASDAQ:SPPI)\nInvestors Affected : December 27, 2018 - August 5, 2021\nA class action has commenced on behalf of certain shareholders in Spectrum Pharmaceuticals, Inc. The filed complaint alleges that defendants made materially false and/or misleading statements and/or failed to disclose that: (i) the manufacturing facility for ROLONTIS, an investigational granulocyte-colony stimulating factor analog, maintained deficient controls and/or procedures; (ii) the foregoing deficiencies decreased the likelihood that the Food and Drug Administration would approve the ROLONTIS biologics license application (\"BLA\") in its current form; (iii) Spectrum had therefore materially overstated the ROLONTIS BLA's approval prospects; and (iv) as a result, the Company's public statements were materially false and misleading at all relevant times.\nShareholders may find more information at https://securitiesclasslaw.com/securities/spectrum-pharmaceuticals-inc-loss-submission-form/?id=19831&from=1\n\nThe Gross Law Firm is committed to ensuring that companies adhere to responsible business practices and engage in good corporate citizenship. The firm seeks recovery on behalf of investors who incurred losses when false and/or misleading statements or the omission of material information by a Company lead to artificial inflation of the Company's stock. Attorney advertising. Prior results do not guarantee similar outcomes.\nCONTACT:The Gross Law Firm15 West 38th Street, 12th floorNew York, NY, 10018Email: dg@securitiesclasslaw.comPhone: (212) 537-9430Fax: (833) 862-7770\nSOURCE: The Gross Law Firm\n\nView source version on accesswire.com: \n\nhttps://www.accesswire.com/665413/The-Gross-Law-Firm-Announces-Class-Actions-on-Behalf-of-Shareholders-of-ANVS-SAVA-and-SPPI","news_type":1},"isVote":1,"tweetType":1,"viewCount":1018,"commentLimit":10,"likeStatus":false,"favoriteStatus":false,"reportStatus":false,"symbols":[],"verified":2,"subType":0,"readableState":1,"langContent":"CN","currentLanguage":"CN","warmUpFlag":false,"orderFlag":false,"shareable":true,"causeOfNotShareable":"","featuresForAnalytics":[],"commentAndTweetFlag":false,"andRepostAutoSelectedFlag":false,"upFlag":false,"length":25,"xxTargetLangEnum":"ZH_CN"},"commentList":[],"hasMoreComment":false,"orderType":2}